---
title: Investigating PET Responses to Treatment in Nodular Lymphocyte-Predominant
  Hodgkin Lymphoma
date: '2023-10-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37785523/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231003180759&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSION: Based on our cohort, we found that patients with NLPHL had
  a lower complete metabolic response to CT (∼75%) compared to cHL (∼85-90%) and PET-response
  was improved following RT for those receiving CMT. There was no significant difference
  in PET-response for those with variant versus typical immunoarchitectural patterns.
  Our findings will allow for the development of PET response-adapted therapy for
  ...'
disable_comments: true
---
CONCLUSION: Based on our cohort, we found that patients with NLPHL had a lower complete metabolic response to CT (∼75%) compared to cHL (∼85-90%) and PET-response was improved following RT for those receiving CMT. There was no significant difference in PET-response for those with variant versus typical immunoarchitectural patterns. Our findings will allow for the development of PET response-adapted therapy for ...